Provides that there shall be a representative of the drug or medical device manufacturer industry on the state board of pharmacy.
Impact
The inclusion of a representative from the drug or medical device industry is expected to influence the state’s regulatory framework concerning pharmacy practices. Proponents argue that it would provide valuable insights into the innovation and practical challenges faced by manufacturers, thus allowing the board to make informed decisions that affect the industry. This change may lead to more collaborative relations between pharmacy oversight and manufacturing entities, potentially benefiting patients and pharmacies alike through improved access to important medical innovations.
Summary
Bill A09671 proposes an amendment to the New York Education Law to include a representative from the drug or medical device manufacturer industry on the state board of pharmacy. The board currently comprises licensed pharmacists and pharmacy technicians, and this bill aims to diversify the industry's representation, recognizing the role of manufacturers in discussions about pharmaceuticals and medical devices. As the bill stands, it seeks to maintain nine pharmacists and two registered pharmacy technicians, adding one industry representative to enhance the board's expertise in relevant matters.
Contention
Notable points of contention surrounding Bill A09671 may revolve around concerns of conflicts of interest. Critics might argue that having a manufacturer representative could skew the board's decisions in favor of industry interests over public health or patient safety priorities. There is a delicate balance to be struck between ensuring that the board is well-informed by industry perspectives while maintaining a primary focus on the welfare of New York's patients and pharmacy practices. The effectiveness of this proposed change will largely depend on the regulatory measures put in place to ensure that the board acts in the public interest.
Enacts the manufacturer disclosure and transparency act requiring prescription drug manufacturers to notify the attorney general of arrangements between pharmaceutical manufacturers resulting in the delay of the introduction of generic medications.
Enacts the manufacturer disclosure and transparency act requiring prescription drug manufacturers to notify the attorney general of arrangements between pharmaceutical manufacturers resulting in the delay of the introduction of generic medications.
Relates to the definition of New York state labelled beer; provides that a licensed farm brewery shall manufacture or sell New York state labelled beer and may manufacture or sell beer other than New York state labelled beer that the licensee has manufactured provided that certain conditions are met.
Provides that the prescribing, dispensing, or receipt of mifepristone or any drug used for medication abortion shall not be considered a criminal conversion act under certain circumstances; provides that mifepristone or any drug used for medication abortion shall not be deemed to be adulterated or misbranded under certain circumstances.
Provides that the prescribing, dispensing, or receipt of mifepristone or any drug used for medication abortion shall not be considered a criminal conversion act under certain circumstances; provides that mifepristone or any drug used for medication abortion shall not be deemed to be adulterated or misbranded under certain circumstances.
Enacts the New York state pharmaceutical drug manufacturer and wholesaler disclosure act; requires pharmaceutical drug manufacturers and wholesalers to annually report to the New York department of health, for disclosure to the general public, all of its gifts to health care practitioners that prescribe drugs when such gifts have a value of seventy-five dollars or more; authorizes the commissioner of health to impose penalties and promulgate necessary rules and regulations.